All In Biotech

Drug Trial Radar · NCT07489209

A Dose-exploration Study of EDP167 in HoFH

A Multicenter, Dose-exploration, Open-label Phase II Study to Evaluate the Efficacy and Safety of EDP167 in Adult Patients With Homozygous Familial Hypercholesterolaemia

Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Feb 6, 2026

Primary completion

Oct 4, 2026

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Eddingpharm (Zhuhai) Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dyslipidemia conditions. This is a dose exploration study in Homozygous Familial Hypercholesterolaemia (HoFH) patients to evaluate the efficacy and safety and pharmacokinetics (PK)/pharmacodynamics (PD) profiles of multiple EDP167 injections.

Conditions

  • Homozygous Familial Hypercholesterolemia (HoFH)

Interventions

  • EDP167Drug

    EDP167 sc injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the change from baseline in serum low-density lipoprotein cholesterol (LDL-C) level at week 24 of the main study phase.Time frame: Up to week 24 of the main study phase

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fuwai Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.